株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の喘息・COPD治療薬市場:2017〜2027年

Global Asthma & COPD Therapies Market 2017-2027

発行 Visiongain Ltd 商品コード 214196
出版日 ページ情報 英文 300 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=154.30円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
世界の喘息・COPD治療薬市場:2017〜2027年 Global Asthma & COPD Therapies Market 2017-2027
出版日: 2017年09月06日 ページ情報: 英文 300 Pages
概要

世界の喘息・COPD治療薬市場は2016年に329億米ドルとなりました。同市場は今後CAGR5.6%で拡大するとみられています。抗炎症薬分野が最速で拡大しており、CAGR7.6%と予測されています。

当レポートでは、世界の喘息・COPD治療薬市場について調査し、今後の収益予測、種類別動向、地域別動向、および市場に参入する主要企業のプロファイルなどをまとめています。

第1章 当レポートの概要

第2章 イントロダクション

  • 医薬品業界:概要
  • 呼吸器疾患の分類
  • 喘息とは
  • 慢性閉塞性肺疾患 (COPD) とは
  • 喘息・COPD治療における主な薬剤クラス
  • 治験段階
  • 当レポートの範囲

第3章 世界市場

  • 治療分野別市場
  • 2016年の市場
  • 治療分野別売上予測
  • 薬剤クラス別売上予測
  • 併用薬が市場をリード
  • セグメントシェアの変動
  • 動向と発展

第4章 気管支拡張剤単剤療法市場

第5章 抗炎症薬市場

第6章 併用薬市場

第7章 主要国市場

  • 地域別分類
  • 地域別予測
  • 米国
  • 日本
  • EU5か国
  • BRIC諸国
  • メキシコ

第8章 主要企業

  • 競争激化
  • 2016年の主要企業
  • 2016〜2027年の主要企業
  • 市場シェアの変動
  • GSK
  • Boehringer Ingelheim
  • AstraZeneca
  • Merck & Co.(Merck)
  • Novartis
  • Roche
  • Teva

第9章 治療薬パイプライン分析

第10章 市場定性分析

  • SWOT分析

第11章 結論

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0234

Title:
GLOBAL ASTHMA & COPD THERAPIES MARKET 2017-2027
Bronchodilator Monotherapy, Anticholinergics, Short-acting Beta-Agonists (SABAs), Long-acting Beta-Agonists (LABAs), Long-acting Muscarinic Antagonists (LAMAs), Anti-Inflammatory Drugs, Corticosteroids, Anti-Leukotrienes, Monoclonal Antibodies, Combination Drugs.

The global asthma & COPD therapies market was valued at $32.9bn in 2016 and is projected to grow at a CAGR of 5.6% in the first half of the forecast period. The Anti-inflammatory Drugs submarket will be the fastest growing submarket in the first half of the forecast period. This submarket is estimated to grow at a CAGR of 7.6%.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 300-page report you will receive 113 tables and 130 figures - all unavailable elsewhere.

The 300-page report provides clear detailed insight into the global asthma & COPD therapies market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Global Asthma & COPD Therapies Market forecasts from 2017-2027, further broken down into:
    • Global Asthma Therapies Market forecasts
    • Global COPD Therapies Market forecasts
  • Revenue forecasts of the three main drug classes of the global asthma & COPD therapies market:
    • Bronchodilators monotherapy
    • Anti-inflammatory drugs
    • Combination drugs
  • Revenue forecast for the Bronchodilators monotherapy market by Type and revenue forecast of the leading drugs:
    • Short-acting beta2-agonists (SABAs): Ventolin, ProAir, Proventil, Xopenex
    • Long-acting beta2-agonists (LABAs): Brovana, Foradil, Arcapta/Onbrez, Serevent,
    • Anticholinergics: Spiriva, Atrovent, Eklira/Tudorza/Bretaris
  • Revenue forecast for the Anti-inflammatory drugs market by Type and revenue forecast of the leading drugs:
    • Corticosteroids: Pulmicort, Flixotide/Flovent, QVAR, Asmanex
    • Anti-leukotrienes: Singulair
    • Monoclonal antibodies (mAbs): Xolair, Cinquil/Cinquair, Nucala, Benralizumab, Lebrikizumab, Dupilumab
  • Revenue forecast for the Combination drugs market and the leading drugs:
    • Advair/Seretide, Symbicort, Combivent, Dulera, Relvar/Breo
  • This report provides individual revenue forecasts from 2017-2027 for these regional and national markets:
    • The US
    • Japan
    • EU5: Germany, France, UK, Italy, Spain
    • BRIC: Brazil, Russia, India, China
    • Mexico
    • Other Countries
  • This report discusses the leading companies in the global asthma & COPD therapies market:
    • GSK
    • Boehringer Ingelheim
    • AstraZeneca
    • Novartis
    • Merck
    • Roche
    • Teva
  • This report discusses drugs currently in clinical development for treating asthma and COPD.
  • This report discusses the SWOT analysis as well as porter's five forces analysis of the global asthma & COPD therapies market.

Visiongain's study is intended for anyone requiring commercial analyses for the global asthma & COPD therapies market. You find data, trends and predictions.

Buy our report today Global Asthma & COPD Therapies Market 2017-2027: Bronchodilator Monotherapy, Anticholinergics, Short-acting Beta-Agonists (SABAs), Long-acting Beta-Agonists (LABAs), Long-acting Muscarinic Antagonists (LAMAs), Anti-Inflammatory Drugs, Corticosteroids, Anti-Leukotrienes, Monoclonal Antibodies, Combination Drugs.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Asthma and COPD Therapies Market Overview
  • 1.2. Global Asthma and COPD Therapies Market Segmentation
  • 1.3. Why You Should Read This Report
  • 1.4. How This Report Delivers
  • 1.5. Key Questions Answered by This Analytical Report
  • 1.6. Who is This Report For?
  • 1.7. Methodology
  • 1.8. Frequently Asked Questions(FAQ)
  • 1.9. Associated Visiongain Reports
  • 1.10. About Visiongain

2. Introduction to Asthma and COPD Therapies

  • 2.1. The Pharmaceutical Industry: A Very Brief Overview
  • 2.2. Classifying Respiratory Diseases: Obstructive and Restrictive
    • 2.2.1. Classifying Respiratory Diseases: Obstructive and Restrictive
  • 2.3. What is Asthma?
    • 2.3.1. Trends in Asthma Prevalence
    • 2.3.2. Pathophysiology of Asthma
    • 2.3.3. Symptoms of Asthma
    • 2.3.4. Causes and Triggers for Asthma
    • 2.3.5. Treatment of Asthma
    • 2.3.6. Guidelines for Asthma Treatment
    • 2.3.7. Drug Treatments for Asthma
    • 2.3.8. Drug Delivery Methods in Asthma
  • 2.4. What is Chronic Obstructive Pulmonary Disease(COPD)?
    • 2.4.1. Trends in COPD Prevalence
    • 2.4.2. Pathophysiology of COPD
    • 2.4.3. Signs and Symptoms of COPD
    • 2.4.4. Treatment of COPD
    • 2.4.5. Drug Treatments for COPD
    • 2.4.6. Guidelines for COPD Treatment
  • 2.5. Major Drug Classes in the Treatment of Asthma and COPD
    • 2.5.1. Bronchodilators
    • 2.5.2. Anti-Inflammatory Drugs
    • 2.5.3. Combination Drugs
  • 2.6. Phases of Clinical Trials
  • 2.7. Scope of this Report

3. Asthma and COPD Therapies: Global Market 2016-2027

  • 3.1. The Global Respiratory Drugs Market by Therapeutic Area
  • 3.2. The Global Asthma and COPD Therapies Market in 2016
    • 3.2.1. Leading Asthma and COPD Therapies
    • 3.2.2. Leading Companies in the Asthma and COPD Therapies Market
  • 3.3. Global Asthma and COPD Therapies Market: Sales Forecast by Therapeutic Area, 2016-2027
    • 3.3.1. Global Asthma Therapies Market: Sales Forecast, 2016-2027
    • 3.3.2. Global COPD Therapies Market: Sales Forecast 2016-2027
  • 3.4. Global Asthma and COPD Therapies Market: Sales Forecast by Drug Class 2016-2027
  • 3.5. Combination Drugs Lead the Asthma and COPD Therapies Market
  • 3.6. How Will Segmental Shares Change to 2027
    • 3.6.1. Global Asthma and COPD Therapies Market: Drivers and Restraints 2016-2027
  • 3.7. Asthma and COPD Therapies: Trends and Developments
    • 3.7.1. FDA Requires Replacement of CFC Inhalers with HFA Inhalers
    • 3.7.2. The WISDOM Trial: Will Steroids Lose Their Role in COPD?

4. Bronchodilator Monotherapy Market 2016-2027

  • 4.1. Introduction to Bronchodilator Monotherapy
  • 4.2. The Bronchodilator Monotherapy Market in 2016
    • 4.2.1. Leading Bronchodilators in 2016
    • 4.2.2. Bronchodilator Monotherapy: Market Forecast 2016-2027
    • 4.2.3. How Will Market Shares by Drug Class Change to 2027?
  • 4.3. The Anticholinergics Market 2016-2027
    • 4.3.1. Leading Anticholinergics in 2016
    • 4.3.2. Anticholinergics: Market Forecast 2016-2027
    • 4.3.3. Market Share of Leading Anticholinergics to 2027
    • 4.3.4. Spiriva(tiotropium. Boehringer Ingelheim)
    • 4.3.5. Atrovent(ipratropium, Boehringer Ingelheim)
    • 4.3.6. Eklira/Tudorza/Bretaris(alcidinium, AstraZeneca/Menarini)
  • 4.4. The SABAs Market 2017-2017
    • 4.4.1. Leading SABAs in 2016
    • 4.4.2. SABAs: Market Forecast 2016-2027
    • 4.4.3. Market Share of Leading SABAs to 2027
    • 4.4.4. Ventolin(salbutamol, GSK)
    • 4.4.5. ProAir(salbutamol, Teva)
    • 4.4.6. Proventil(salbutamol, Merck)
    • 4.4.7. Xopenex(levosalbutamol, Dainippon Sumitomo)
  • 4.5. The Long-Acting Beta2-Agonist(LABA) Market 2016-2027
    • 4.5.1. Leading LABAs in 2016
    • 4.5.2. LABAs: Market Forecast 2016-2027
    • 4.5.3. Market Share of Leading LABAs to 2027
    • 4.5.4. Foradil(formoterol, Merck/Novartis)
    • 4.5.5. Brovana(arfomoterol, Dainippon Sumitomo)
    • 4.5.6. Arcapta/Onbrez(indacaterol, Novartis)
    • 4.5.7. Severent(salmeterol, GSK)

5. Anti-inflammatory Drugs Market 2016-2027

  • 5.1. Introduction to Anti-Inflammatory Drugs
  • 5.2. The Anti-Inflammatory Drugs Market in 2016
    • 5.2.1. Leading Anti-Inflammatory Drugs in 2016
    • 5.2.2. Anti-Inflammatory Drugs: Market Forecast 2016-2027
    • 5.2.3. How Will Market Shares by Drug Class Change to 2027?
  • 5.3. The Corticosteroids Market 2016-2027
    • 5.3.1. Leading Corticosteroids in 2016
    • 5.3.2. Corticosteroids: Market Forecast 2016-2027
    • 5.3.3. Market Share of Leading Corticosteroids to 2027
    • 5.3.4. Flixotide/Flovent(fluticasone propionate, GSK)
    • 5.3.5. Pulmicort(budesonide, AstraZeneca)
    • 5.3.6. QVAR(beclometasone, Teva)
    • 5.3.7. Asmanex(mometasone, Merck)
  • 5.4. The Anti-Leukotrienes Market 2016-2027
    • 5.4.1. Leading Anti-Leukotrienes in 2016
    • 5.4.2. Anti-Leukotrienes: Market Forecast 2016-2027
    • 5.4.3. Market Share of Leading Anti-Leukotrienes to 2027
    • 5.4.4. Singulair(montelukast, Merck)
  • 5.5. The Monoclonal Antibodies Market 2016-2027
    • 5.5.1. Monoclonal Antibodies: Market Forecast 2016-2027
    • 5.5.2. Market Share of Leading Monoclonal Antibodies to 2027
    • 5.5.3. Xolair(omalizumab, Novartis/Roche)
    • 5.5.4. Cinquil/Cinquair(reslizumab, Teva)
    • 5.5.5. Nucala(Mepolizumab, GSK)
    • 5.5.6. Benralizumab(MEDI-563, AstraZeneca/Kyowa Hakko Kirin)
    • 5.5.7. Lebrikizumab(RG3637, Roche)
    • 5.5.8. Dupilumab(REGN668, Regeneron/Sanofi)

6. Combination Drugs Market 2016-2027

  • 6.1. Introduction to Combination Drugs
    • 6.1.1. Leading Combination Drugs in 2016
    • 6.1.2. Combination Drugs: Market Forecast 2016-2027
    • 6.1.3. How Will Market Shares by Drug Change to 2027?
    • 6.1.4. Advair/Seretide(fluticasone/salmeterol, GSK)
    • 6.1.5. Symbicort(budesonide/formoterol fumarate, AstraZeneca)
    • 6.1.6. Combivent(ipratropium/salbutamol, Boehringer Ingelheim)
    • 6.1.7. Dulera(formoterol/mometasone, Merck)
    • 6.1.8. Breo/Relvar Ellipta(vilanterol/fluticasone furoate, GSK)
  • 6.2. Recently Launched Combination Drugs

7. Leading National Markets 2016-2027

  • 7.1. Regional Breakdown of the Global Asthma and COPD Therapies Market
  • 7.2. Global Asthma and COPD Therapies Market; Regional Forecasts 2016-2027
    • 7.2.1. How Will Regional Market Shares Change to 2027?
    • 7.2.2. National Breakdown of the Global asthma and COPD Therapies Market
    • 7.2.3. Global Asthma and COPD Therapies Market: National Markets Forecast 2016-2027
    • 7.2.4. How Will National Market Shares Change to 2027?
  • 7.3. The US Asthma and COPD Therapies Market 2016-2027
    • 7.3.1. The US Asthma and COPD Therapies Market Forecast 2016-2027
    • 7.3.2. US Asthma and COPD Therapies Market Trends and Developments
  • 7.4. Japanese Asthma and COPD Therapies Market 2016-2027
    • 7.4.1. Japanese Asthma and COPD Therapies Market Forecast 2016-2027
    • 7.4.2. Japanese Asthma and COPD Therapies Market: Trends and Developments
  • 7.5. EU5 Asthma and COPD Therapies Market 2016-2027
    • 7.5.1. German Asthma and COPD Therapies Market Forecast 2016-2027
    • 7.5.2. French Asthma and COPD Therapies Market Forecast 2016-2027
    • 7.5.3. UK Asthma and COPD Therapies Market Forecast 2016-2027
    • 7.5.4. Italian Asthma and COPD Therapies Market Forecast 2016-2027
    • 7.5.5. Spanish Asthma and COPD Therapies Market Forecast 2016-2027
    • 7.5.6. EU5 Asthma and COPD Therapies Market: Trends and Developments
  • 7.6. BRIC Asthma and COPD Therapies Market 2016-2027
    • 7.6.1. Chinese Asthma and COPD Therapies Market Forecast 2016-2027
    • 7.6.2. Chinese Asthma and COPD Therapies Market: Trends and Developments
    • 7.6.3. Brazilian Asthma and COPD Therapies Market Forecast 2016-2027
    • 7.6.4. Brazilian Asthma and COPD Therapies Market: Trends and Developments
    • 7.6.5. Indian Asthma and COPD Therapies Market Forecast 2016-2027
    • 7.6.6. Indian Asthma and COPD Therapies Market: Trends and Developments
    • 7.6.7. Russian Asthma and COPD Therapies Market Forecast 2016-2027
    • 7.6.8. Russian Asthma and COPD Therapies Market: Trends and Developments
  • 7.7. Mexican Asthma and COPD Therapies Market 2016-2027
    • 7.7.1. Mexican Asthma and COPD Therapies Market Forecast 2016-2027
    • 7.7.2. Mexican Asthma and COPD Therapies Market: Trends and Developments

8. Leading Companies in the Asthma and COPD Therapies Market

  • 8.1. Asthma and COPD Therapies: Increasing Competition
  • 8.2. Leading Companies in Asthma and COPD in 2016
  • 8.3. Leading Companies: Market Forecast 2016-2027
  • 8.4. How Will Leading Companies' Market Shares Change to 2027?
  • 8.5. GSK
    • 8.5.1. GSK: Asthma and COPD Therapies
    • 8.5.2. GSK: Sales Forecast 2016-2027
    • 8.5.3. GSK: Products in Development
    • 8.5.4. GSK: Recent Developments
  • 8.6. Boehringer Ingelheim
    • 8.6.1. Boehringer Ingelheim: Asthma and COPD Therapies
    • 8.6.2. Boehringer Ingelheim: Sales Forecast 2016-2027
    • 8.6.3. Boehringer Ingelheim: Asthma and COPD Product Development Ceased
    • 8.6.4. Boehringer Ingelheim: Recent Developments
  • 8.7. AstraZeneca
    • 8.7.1. AstraZeneca: Asthma and COPD Therapies
    • 8.7.2. AstraZeneca: Sales Forecast 2016-2027
    • 8.7.3. AstraZeneca: Products in Development
    • 8.7.4. AstraZeneca: Recent Developments
  • 8.8. Merck & Co.(Merck)
    • 8.8.1. Merck: Asthma and COPD Therapies
    • 8.8.2. Merck: Sales Forecast 2016-2027
    • 8.8.3. Merck: Products in Development
    • 8.8.4. Merck: Recent Developments
  • 8.9. Novartis
    • 8.9.1. Novartis: Asthma and COPD Therapies
    • 8.9.2. Novartis: Sales Forecast 2016-2027
    • 8.9.3. Novartis: Products in Development
    • 8.9.4. Novartis: Recent Developments
  • 8.10. Roche
    • 8.10.1. Roche: Asthma and COPD Therapies
    • 8.10.2. Roche: Sales Forecast 2016-2027
    • 8.10.3. Roche: Products in Development
  • 8.11. Teva
    • 8.11.1. Teva: Asthma and COPD Therapies
    • 8.11.2. Teva: Sales Forecast 2016-2027
    • 8.11.3. Teva: Products in Development
    • 8.11.4. Teva: Recent Developments

9. Asthma and COPD Therapies Pipeline Analysis 2016-2027

  • 9.1. A Strong Asthma and COPD Pipeline
  • 9.2. The Bronchodilators Pipeline
    • 9.2.1. Bronchodilators: Phase 3 Pipeline
  • 9.3. The Anti-Inflammatory Drugs Pipeline
    • 9.3.1. Anti-Inflammatory Drugs: Phase 3 Pipeline
  • 9.4. The Combination Drugs Pipeline
    • 9.4.1. Combination Drugs: Phase 3 Pipeline
  • 9.5. Other Asthma and COPD Drugs Pipeline

10. Qualitative Analysis of the Asthma and COPD Therapies Market 2016-2027

  • 10.1. SWOT Analysis of the Asthma and COPD Therapies Market
  • 10.2. Strengths
    • 10.2.1. Increasing Prevalence and Disease Burden
    • 10.2.2. High Costs of Treatment
    • 10.2.3. The Changing Perception of COPD
    • 10.2.4. Patient Education: Understanding the Severity of Respiratory Disease
    • 10.2.5. Lifecycle Management Strategies to Counter Patent Expiry
    • 10.2.6. Advanced Inhaler Technologies to Counter Generic Erosion
    • 10.2.7. Developments in Diagnostics
  • 10.3. Weaknesses
    • 10.3.1. Under-Diagnosis: the ‘Ghost Population'
    • 10.3.2. Side-Effects of Drug Classes
    • 10.3.3. Patent Cliff for Devices
    • 10.3.4. Low Patient Adherence
    • 10.3.5. Costing Pressures in both Developed and Emerging Markets
  • 10.4. Opportunities
    • 10.4.1. Patient Phenotyping and Personalised Medicine
    • 10.4.2. A Strong R&D Pipeline
    • 10.4.3. Ultra-Long-Acting Beta2-Agonists
    • 10.4.4. Muscarinic Antagonists and Beta2-Agonists(MABAs)
    • 10.4.5. Monoclonal Antibodies
    • 10.4.6. LAMA/LABA Combinations
    • 10.4.7. Opportunities in Telehealth
  • 10.5. Threats
    • 10.5.1. Patent Expiry and Generic Competition
    • 10.5.2. Pharmacy Benefit Managers and Cost Control
    • 10.5.3. The WISDOM Trial Could Reduce Steroid Use in COPD
  • 10.6. Porter's Five Forces Analysis of the Asthma and COPD Therapies Market
    • 10.6.1. Rivalry among Competitors [Medium]
    • 10.6.2. Threat of New Entrants [Medium]
    • 10.6.3. Power of Suppliers [Medium]
    • 10.6.4. Power of Buyers [High]
    • 10.6.5. Threat of Substitutes [Low]

11. Conclusions

  • 11.1. Asthma and COPD Therapies: A Maturing Market
  • 11.2. The Global Asthma and COPD Therapies Market in 2016
  • 11.3. Current Leading Asthma and COPD Therapies Segments
    • 11.3.1. Leading Asthma and COPD Therapies
    • 11.3.2. Leading Asthma and COPD Therapies Companies
  • 11.4. Leading Regional and National Markets
  • 11.5. Global Asthma and COPD Therapies Market Forecast 2016-2027
  • 11.6. The Future of the Asthma and COPD Therapies Market
    • 11.6.1. Growth in Anti-Inflammatory and Combination Drugs
    • 11.6.2. Personalised Medicine
    • 11.6.3. Unmet Needs in Asthma and COPD
  • 11.7. Strategies for Growth in 2016-2027

Appendices

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain report evaluation form

List of Tables

  • Table 2.1: Classification of Respiratory Diseases, 2016
  • Table 2.2: Causes of Asthma, 2016
  • Table 2.3: Triggers of Asthma, 2016
  • Table 2.4: Clinical Trial Phases
  • Table 3.1: World Respiratory Drugs Market: Revenues($m) and Market Shares(%) by Therapeutic Area, 2016
  • Table 3.2: Top 10 Asthma and COPD Therapies: Revenue($m) and Market Shares(%), 2016
  • Table 3.3: World Asthma and COPD Therapies Market Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 3.4: World Asthma Therapies Market Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 3.5: World COPD Therapies Market Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 3.6: Global Asthma and COPD Therapies Market Forecast: Revenue($m), AGR(%) and CAGR(%), by Drug Class, 2016-2027
  • Table 3.7: Market Shares(%) of Leading Asthma and COPD Therapies Market Segments, by Drug Class, 2016, 2021 and 2027
  • Table 4.1: Bronchodilator Monotherapy Market: Revenues($m) and Market Shares(%) by Drug Class, 2016
  • Table 4.2: Leading Bronchodilators: Revenues($m) and Market Shares(%), 2016
  • Table 4.3: Bronchodilator Monotherapy Market Forecast: Revenues($m), AGR(%) and CAGR(%), by Drug Class, 2016-2027
  • Table 4.4: Leading Anticholinergics: Revenues($m) and Market Shares(%), 2016
  • Table 4.5: Anticholinergics Market Forecast: Revenues($m), AGR(%) and CAGR(%), by Drug, 2016-2027
  • Table 4.6: Anticholinergics Market: Market Shares(%) by Drug, 2016, 2021 and 2027
  • Table 4.7: Boehringer Ingelheim: Spiriva Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 4.8: Boehringer Ingelheim: Atrovent Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 4.9: AstraZeneca/Menarini: Eklira/Tudorza/Bretaris Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 4.10: Leading SABAs in 2016
  • Table 4.11: SABAs Market Forecast: Revenues($m), AGR(%) and CAGR(%), by Drug, 2016-2027
  • Table 4.12: SABAs Market: Market Shares(%) by Drug, 2016, 2021 and 2027
  • Table 4.13: GSK: Ventolin Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 4.14: Teva: ProAir Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 4.15: Merck: Proventil Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 4.16: Dainippon Sumitomo: Xopenex Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 4.17: Leading LABAs: Revenues($m) and Market Shares(%), 2016
  • Table 4.18: LABAs Market Forecast: Revenues($m), AGR(%) and CAGR(%), by Drug, 2016-2027
  • Table 4.19: Leading LABAs: Market Shares(%) by Drug, 2016, 2021 and 2027
  • Table 4.20: Merck/Novartis: Foradil Revenue($m), AGR(%) and CAGR(%),2016-2027
  • Table 4.21: Dainippon Sumitomo: Brovana Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 4.22: Novartis: Arcapta/Onbrez Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 4.23: GSK: Serevent Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 5.1: Anti-Inflammatory Drugs Market: Revenues($m) and Market Shares(%) by Drug Class, 2016
  • Table 5.2: Leading Anti-Inflammatory Drugs: Revenues($m) and Market Shares(%), 2016
  • Table 5.3: Anti-Inflammatory Drugs Market Forecast: Revenues($m), AGR(%) and CAGR(%), by Drug Class, 2016-2027
  • Table 5.4: Anti-Inflammatory Drugs Market: Revenues($m) and Market Shares(%) by Drug Class, 2021 and 2027
  • Table 5.5: Leading Corticosteroids: Revenues($m) and Market Shares(%), 2016
  • Table 5.6: Corticosteroids Market Forecast: Revenues($m), AGR(%) and CAGR(%), by Drug, 2016-2027
  • Table 5.7: Corticosteroids Market: Market Share(%) by Drug, 2016, 2021 and 2027
  • Table 5.8: GSK: Flixotide/Flovent Revenue($m) and AGR(%), 2016-2027
  • Table 5.9: AstraZeneca: Pulmicort Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 5.10: Teva: QVAR Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 5.11: Merck: Asmanex Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 5.12: Leading Anti-Leukotrienes: Revenues($m) and Market Shares(%), 2016
  • Table 5.13: Anti-Leukotrienes Market Forecast: Revenues($m), AGR(%) and CAGR(%), by Drug, 2016-2027
  • Table 5.14: Anti-Leukotrienes Market: Market Shares(%) by Drug, 2016, 2021 and 2027
  • Table 5.15: Merck: Singulair Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 5.16: Monoclonal Antibodies Market Forecast: Revenues($m), AGR(%) and CAGR(%), by Drug, 2016-2027
  • Table 5.17: Monoclonal Antibodies Market: Market Shares(%) by Drug, 2016, 2021 and 2027
  • Table 5.18: Novartis/Roche: Xolair Asthma Indication Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 5.19: Teva: Cinquil/Cinquair Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 5.20: GSK: Nucala Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 5.21: AstraZeneca/Kyowa Hakko Kirin: Benralizumab Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 5.22: Roche: Lebrikizumab Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 5.23: Regeneron/Sanofi: Dupilumab Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 6.1: Leading Combination Drugs: Revenues($m) and Market Share(%), 2016
  • Table 6.2: Combination Drugs Market Forecast: Revenues($m), AGR(%) and CAGR(%), by Drug, 2016-2027
  • Table 6.3: Combination Drugs Market: Market Shares(%) by Drug, 2016, 2021 and 2027
  • Table 6.4: GSK: Advair/Seretide Revenue($m) and AGR(%), 2016-2027
  • Table 6.5: AstraZeneca: Symbicort Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 6.6: Boehringer Ingelheim: Combivent Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 6.7: Merck: Dulera Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 6.8: GSK: Relvar/Breo Revenue($m), AGR(%) and CAGR(%), 2016-202
  • Table 7.1: World Asthma and COPD Therapies Market: Revenues($m) and Market Shares(%) by Region, 2016
  • Table 7.2: World Asthma and COPD Therapies Market Forecast: Revenues($m), AGR(%) and CAGR(%) by Region, 2016-2027
  • Table 7.3: Market Shares(%) of Leading Regional Asthma and COPD Therapies Markets, 2016, 2021 and 2027
  • Table 7.4: World Asthma and COPD Therapies Market: Revenues($m) and Market Shares(%) by National Market, 2016
  • Table 7.5: World Asthma and COPD Therapies Market Forecast: Revenues($m), AGR(%) and CAGR(%) by National Market, 2016-2027
  • Table 7.5: World Asthma and COPD Therapies Market Forecast: Revenues($m), AGR(%) and CAGR(%) by National Market, 2016-2027(continued)
  • Table 7.6: Market Shares(%) of Leading National Asthma and COPD Therapies Markets, 2016, 2021 and 2027
  • Table 7.7: US Asthma and COPD Therapies Market Forecast: Revenues($m), AGR(%) and CAGR(%), 2016-2027
  • Table 7.8: Japanese Asthma and COPD Therapies Market Forecast: Revenues($m), AGR(%) and CAGR(%), 2016-2027
  • Table 7.9 : U5 Asthma and COPD Therapies Market Forecast: Revenues($m), AGR(%) and CAGR(%) by National Market, 2016-2027
  • Table 7.10: German Asthma and COPD Therapies Market Forecast: Revenues($m), AGR(%) and CAGR(%), 2016-2027
  • Table 7.11: French Asthma and COPD Therapies Market Forecast: Revenues($m), AGR(%) and CAGR(%), 2016-2027
  • Table 7.12: UK Asthma and COPD Therapies Market Forecast: Revenues($m), AGR(%) and CAGR(%), 2016-2027
  • Table 7.13: Italian Asthma and COPD Therapies Market Forecast: Revenues($m), AGR(%) and CAGR(%), 2016-2027
  • Table 7.14: Spanish Asthma and COPD Therapies Market Forecast: Revenues($m), AGR(%) and CAGR(%), 2016-2027
  • Table 7.15: BRIC Asthma and COPD Therapies Market Forecast: Revenues($m), AGR(%) and CAGR(%) by National Market, 2016-2027
  • Table 7.16: Chinese Asthma and COPD Therapies Market Forecast: Revenues($m), AGR(%) and CAGR(%), 2016-2027
  • Table 7.17: Brazilian Asthma and COPD Therapies Market Forecast: Revenues($m), AGR(%) and CAGR(%), 2016-2027
  • Table 7.18: Indian Asthma and COPD Therapies Market Forecast: Revenues($m), AGR(%) and CAGR(%), 2016-2027
  • Table 7.19: Russian Asthma and COPD Therapies Market Forecast: Revenues($m), AGR(%) and CAGR(%), 2016-2027
  • Table 7.20: Mexican Asthma and COPD Therapies Market Forecast: Revenues($m), AGR(%) and CAGR(%), 2016-2027
  • Table 8.1: Leading Asthma and COPD Drug Manufacturers: Asthma and COPD Drugs Revenue($m), Market Share(%), 2016
  • Table 8.2: Leading Asthma and COPD Drug Manufacturers: Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 8.3: Leading Asthma and COPD Drug Manufacturers: Revenues($m) and Market Shares(%), 2021 and 2027
  • Table 8.4: GSK: Overview, 2016
  • Table 8.5: GSK: Asthma and COPD Therapies Revenue($m), Revenue Share(%) by Drug, 2016
  • Table 8.6: GSK: Asthma and COPD Therapies Revenue($m), AGR(%), CAGR(%) by Drug, 2016-2027
  • Table 8.7: GSK: Asthma and COPD Therapies Pipeline, 2016
  • Table 8.8: Boehringer Ingelheim: Overview, 2016
  • Table 8.9: Boehringer Ingelheim: Asthma and COPD Therapies Revenue($m), Revenue Share(%) by Drug, 2016
  • Table 8.10: Boehringer Ingelheim: Asthma and COPD Therapies Revenue($m), AGR(%) and CAGR(%), by Drug, 2016-2027
  • Table 8.11: AstraZeneca: Overview, 2016
  • Table 8.12: AstraZeneca: Asthma and COPD Therapies Revenue($m), Revenue Share(%) by Drug, 2016
  • Table 8.13: AstraZeneca: Asthma and COPD Therapies Revenue($m), AGR(%) and CAGR(%), by Drug, 2016-2027
  • Table 8.14: AstraZeneca: Asthma and COPD Therapies Pipeline, 2016
  • Table 8.15: Merck: Overview, 2016
  • Table 8.16: Merck: Asthma and COPD Therapies Revenue($m), Revenue Share(%) by Drug, 2016
  • Table 8.17: Merck: Asthma and COPD Therapies Revenue($m), AGR(%), CAGR(%) by Drug, 2016-2027
  • Table 8.18: Novartis: Overview, 2016
  • Table 8.19: Novartis: Asthma and COPD Therapies Revenue($m), Revenue Share(%) by Drug, 2016
  • Table 8.20: Novartis: Asthma and COPD Therapies Revenue($m), AGR(%), CAGR(%) by Drug, 2016-2027
  • Table 8.21: Novartis: Asthma and COPD Therapies Pipeline, 2016
  • Table 8.22: Roche: Overview, 2016
  • Table 8.23: Roche: Asthma and COPD Therapies Revenue($m), AGR(%), CAGR(%) by Drug, 2016-2027
  • Table 8.24: Teva: Overview, 2016
  • Table 8.25: Teva: Asthma and COPD Therapies Revenue($m), Revenue Share(%) by Drug, 2016
  • Table 8.26: Teva: Asthma and COPD Therapies Revenue($m), AGR(%), CAGR(%) by Drug, 2016-2027
  • Table 8.27: Teva: Asthma and COPD Therapies Pipeline, 2016

List of Figures

  • Figure 1.1: Global Asthma and COPD Therapies Market Segmentation Overview, 2016
  • Figure 2.1: Summary of GINA Guidance for Asthma Treatment, 2016
  • Figure 2.2: Summary of GOLD Guidance for COPD Treatment, 2016
  • Figure 3.1: World Respiratory Drugs Market: Revenues($m) by Therapeutic Area, 2016
  • Figure 3.2: World Respiratory Drugs Market: Market Shares(%) by Therapeutic Area, 2016
  • Figure 3.3: Top 10 Asthma and COPD Therapies: Market Shares(%), 2016
  • Figure 3.4: World Asthma and COPD Therapies Market Forecast: Revenue($m) and AGR(%), 2016-2027
  • Figure 3.5: World Asthma Therapies Market Forecast: Revenue($m) and AGR(%), 2016-2027
  • Figure 3.6: World COPD Therapies Market Forecast: Revenue($m) and AGR(%), 2016-2027
  • Figure 3.7: Global Asthma and COPD Therapies Market: Market Shares(%) by Segment, 2016
  • Figure 3.8: Global Asthma and COPD Therapies Market: Market Shares(%) by Segment, 2021
  • Figure 3.9: Global Asthma and COPD Therapies Market: Market Shares(%) by Segment, 2027
  • Figure 3.10: World Asthma and COPD Therapies Market: Drivers and Restraints, 2016-2027
  • Figure 4.1: Bronchodilator Monotherapy Market: Revenues($m) by Drug Class, 2016
  • Figure 4.2: Bronchodilator Monotherapy Market: Market Shares(%) by Drug Class, 2021
  • Figure 4.3: Bronchodilator Monotherapy Market: Market Shares(%) by Drug Class, 2027
  • Figure 4.4: Bronchodilator Monotherapy Market Forecast: Revenue($m) and AGR(%), 2016-2027
  • Figure 4.5: Anticholinergics Market Forecast: Revenue($m) and AGR(%), 2016-2027
  • Figure 4.6: Anticholinergics Market: Market Shares(%) by Drug, 2016
  • Figure 4.7: Anticholinergics Market: Market Shares(%) by Drug, 2021
  • Figure 4.8: Anticholinergics Market: Market Shares(%) by Drug, 2027
  • Figure 4.9: Boehringer Ingelheim: Spiriva Revenue($m) and AGR(%), 2016-2027
  • Figure 4.10: Boehringer Ingelheim: Atrovent Revenue($m) and AGR(%), 2016-2027
  • Figure 4.11: AstraZeneca/Menarini: Eklira/Tudorza/Bretaris Revenue($m) and AGR(%), 2016-2027
  • Figure 4.12: SABAs Market Forecast: Revenue($m) and AGR(%), 2016-2027
  • Figure 4.13: SABAs Market: Market Shares(%) by Drug, 2016
  • Figure 4.14: SABAs Market: Market Shares(%) by Drug, 2021
  • Figure 4.15: SABAs Market: Market Shares(%) by Drug, 2027
  • Figure 4.16: GSK: Ventolin Revenue($m) and AGR(%), 2016-2027
  • Figure 4.17: Teva: ProAir Revenue($m) and AGR(%), 2016-2027
  • Figure 4.18: Merck: Proventil Revenue($m) and AGR(%), 2016-2027
  • Figure 4.19: Dainippon Sumitomo: Xopenex Revenue($m) and AGR(%), 2016-2027
  • Figure 4.20: LABAs Market Forecast: Revenue($m) and AGR(%), 2016-2027
  • Figure 4.21: LABAs Market: Market Shares(%) by Drug, 2016
  • Figure 4.22: LABAs Market: Market Shares(%) by Drug, 2021
  • Figure 4.23: LABAs Market: Market Shares(%) by Drug, 2027
  • Figure 4.24: Merck/Novartis: Foradil Revenue($m) and AGR(%), 2016-2027
  • Figure 4.25: Dainippon Sumitomo: Brovana Revenue($m) and AGR(%), 2016-2027
  • Figure 4.26: Novartis: Arcapta/Onbrez Revenue($m) and AGR(%), 2016-2027
  • Figure 4.27: GSK: Serevent Revenue($m) and AGR(%), 2016-2027
  • Figure 5.1: Anti-Inflammatory Drugs Market: Revenues($m) by Drug Class, 2016
  • Figure 5.2: Anti-Inflammatory Drugs Market: Market Shares(%) by Drug Class, 2016
  • Figure 5.3: Anti-Inflammatory Drugs Market Forecast: Revenue($m) and AGR(%), 2016-2027
  • Figure 5.4: Anti-Inflammatory Drugs Market: Revenues($m) by Drug Class, 2021
  • Figure 5.5: Anti-Inflammatory Drugs Market: Market Shares(%) by Drug Class, 2021
  • Figure 5.6: Anti-Inflammatory Drugs Market: Revenues($m) by Drug Class, 2027
  • Figure 5.7: Anti-Inflammatory Drugs Market: Market Shares(%) by Drug Class, 2027
  • Figure 5.8: Corticosteroids Market Forecast: Revenue($m) and AGR(%), 2016-2027
  • Figure 5.9: Corticosteroids Market: Market Share(%) by Drug, 2016
  • Figure 5.10: Corticosteroids Market: Market Share(%) by Drug, 2021
  • Figure 5.11: Corticosteroids Market: Market Share(%) by Drug, 2027
  • Figure 5.12: GSK: Flixotide/Flovent Revenue($m) and AGR(%), 2016-2027
  • Figure 5.13: AstraZeneca: Pulmicort Revenue($m) and AGR(%), 2016-2027
  • Figure 5.14: Teva: QVAR Revenue($m) and AGR(%), 2016-2027
  • Figure 5.15: Merck: Asmanex Revenue($m) and AGR(%), 2016-2027
  • Figure 5.16: Anti-Leukotrienes Market Forecast: Revenue($m) and AGR(%), 2016-2027
  • Figure 5.17: Anti-Leukotrienes Market: Market Shares(%) by Drug, 2016
  • Figure 5.18: Anti-Leukotrienes Market: Market Shares(%) by Drug, 2021
  • Figure 5.19: Anti-Leukotrienes Market: Market Shares(%) by Drug, 2027
  • Figure 5.20: Merck: Singulair Revenue($m) and AGR(%), 2016-2027
  • Figure 5.21: Monoclonal Antibodies Market Forecast: Revenue($m) and AGR(%), 2016-2027
  • Figure 5.22: Monoclonal Antibodies Market: Market Shares(%) by Drug, 2021
  • Figure 5.23: Monoclonal Antibodies Market: Market Shares(%) by Drug, 2027
  • Figure 5.24: Novartis/Roche: Xolair Asthma Indication Revenue($m) and AGR(%), 2016-2027
  • Figure 5.25: Teva: Cinquil/Cinquair Revenue($m) and AGR(%), 2016-2027
  • Figure 5.26: GSK: Nucala Revenue($m) and AGR(%), 2016-2027
  • Figure 5.27: AstraZeneca/Kyowa Hakko Kirin: Benralizumab Revenue($m) and AGR(%), 2016-2027
  • Figure 5.28: Roche: Lebrikizumab Revenue($m) and AGR(%), 2016-2027
  • Figure 5.29: Regeneron/Sanofi: Dupilumab Revenue($m) and AGR(%), 2016-2027
  • Figure 6.1: Combination Drugs Market Forecast: Revenue($m) and AGR(%), 2016-2027
  • Figure 6.2: Combination Drugs Market: Market Shares(%) by Drug, 2016
  • Figure 6.3: Combination Drugs Market: Market Shares(%) by Drug, 2021
  • Figure 6.4: Combination Drugs Market: Market Shares(%) by Drug, 2027
  • Figure 6.5: GSK: Advair/Seretide Revenue($m) and AGR(%), 2016-2027
  • Figure 6.6: AstraZeneca: Symbicort Revenue($m) and AGR(%), 2016-2027
  • Figure 6.7: Boehringer Ingelheim: Combivent Revenue($m) and AGR(%), 2016-2027
  • Figure 6.8: Merck: Dulera Revenue($m) and AGR(%), 2016-2027
  • Figure 6.9: GSK: Relvar/Breo Revenue($m) and AGR(%), 2016-2027
  • Figure 7.1: World Asthma and COPD Therapies Market: Revenues($m) by Region, 2016
  • Figure 7.2: World Asthma and COPD Therapies Market: Market Shares(%) by Region, 2016
  • Figure 7.3: World Asthma and COPD Therapies Market Forecast: Revenues($m) by Region, 2016-2027
  • Figure 7.4: World Asthma and COPD Therapies Market: Market Shares(%) by Region, 2021
  • Figure 7.5: World Asthma and COPD Therapies Market: Market Shares(%) by Region, 2027
  • Figure 7.6: World Asthma and COPD Therapies Market: Revenues($m) by National Market, 2016
  • Figure 7.7: World Asthma and COPD Therapies Market: Market Shares(%) by National Market, 2016
  • Figure 7.8: World Asthma and COPD Therapies Market: Market Shares(%) by National Market, 2021
  • Figure 7.9: World Asthma and COPD Therapies Market: Market Shares(%) by National Market, 2027
  • Figure 7.10: US Asthma and COPD Therapies Market Forecast: Revenues($m) and AGR(%), 2016-2027
  • Figure 7.11: Japanese Asthma and COPD Therapies Market Forecast: Revenues($m) and AGR(%), 2016-2027
  • Figure 7.12: EU5 Asthma and COPD Therapies Market Forecast: Revenues($m) by National Market, 2016-2027
  • Figure 7.13: German Asthma and COPD Therapies Market Forecast: Revenues($m) and AGR(%), 2016-2027
  • Figure 7.14: French Asthma and COPD Therapies Market Forecast: Revenues($m) and AGR(%), 2016-2027
  • Figure 7.15: UK Asthma and COPD Therapies Market Forecast: Revenues($m), AGR(%) and 2016-2027
  • Figure 7.16: Italian Asthma and COPD Therapies Market Forecast: Revenues($m) and AGR(%), 2016-2027
  • Figure 7.17: Spanish Asthma and COPD Therapies Market Forecast: Revenues($m) and AGR(%), 2016-2027
  • Figure 7.18: BRIC Asthma and COPD Therapies Market Forecast: Revenues($m) by National Market, 2016-2027
  • Figure 7.19: Chinese Asthma and COPD Therapies Market Forecast: Revenues($m) and AGR(%), 2016-2027
  • Figure 7.20: Brazilian Asthma and COPD Therapies Market Forecast: Revenues($m) and AGR(%), 2016-2027
  • Figure 7.21: Indian Asthma and COPD Therapies Market Forecast: Revenues($m) and AGR(%), 2016-2027
  • Figure 7.22: Russian Asthma and COPD Therapies Market Forecast: Revenues($m) and AGR(%), 2016-2027
  • Figure 7.23: Mexican Asthma and COPD Therapies Market Forecast: Revenues($m) and AGR(%), 2016-2027
  • Figure 8.1: Leading Asthma and COPD Drug Manufacturers: Revenue($m), 2016
  • Figure 8.2: Leading Asthma and COPD Drug Manufacturers: Market Share(%), 2016
  • Figure 8.3: Leading Asthma and COPD Drug Manufacturers: Revenues($m), 2021
  • Figure 8.4: Leading Asthma and COPD Drug Manufacturers: Market Shares(%), 2021
  • Figure 8.5: Leading Asthma and COPD Drug Manufacturers: Revenues($m), 2027
  • Figure 8.6: Leading Asthma and COPD Drug Manufacturers: Market Shares(%), 2027
  • Figure 8.7: GSK: Asthma and COPD Therapies Revenue($m) by Drug, 2016
  • Figure 8.8: GSK: Asthma and COPD Therapies Revenue Share(%) by Drug, 2016
  • Figure 8.9: GSK: Asthma and COPD Therapies Revenue($m) and AGR(%), 2016-2027
  • Figure 8.10: Boehringer Ingelheim: Asthma and COPD Therapies Revenue($m) by Drug, 2016
  • Figure 8.11: Boehringer Ingelheim: Asthma and COPD Therapies Revenue Share(%) by Drug, 2016
  • Figure 8.12: Boehringer Ingelheim: Asthma and COPD Therapies Revenue($m) and AGR(%), 2016-2027
  • Figure 8.13: AstraZeneca: Asthma and COPD Therapies Revenue($m) by Drug, 2016
  • Figure 8.14: AstraZeneca: Asthma and COPD Therapies Revenue Share(%) by Drug, 2016
  • Figure 8.15: AstraZeneca: Asthma and COPD Therapies Revenue($m) and AGR(%), 2016-2027
  • Figure 8.16: Merck: Asthma and COPD Therapies Revenue($m) by Drug, 2016
  • Figure 8.17: Merck: Asthma and COPD Therapies Revenue Share(%) by Drug, 2016
  • Figure 8.18: Merck: Asthma and COPD Therapies Revenue($m) and AGR(%), 2016-2027
  • Figure 8.19: Novartis: Asthma and COPD Therapies Revenue($m) by Drug, 2016
  • Figure 8.20: Novartis: Asthma and COPD Therapies Revenue Share(%) by Drug, 2016
  • Figure 8.21: Novartis: Asthma and COPD Therapies Revenue($m) and AGR(%), 2016-2027
  • Figure 8.22: Roche: Asthma and COPD Therapies Revenue($m) and AGR(%), 2016-2027
  • Figure 8.23: Teva: Asthma and COPD Therapies Revenue($m) by Drug, 2016
  • Figure 8.24: Teva: Asthma and COPD Therapies Revenue Share(%) by Drug, 2016
  • Figure 8.25: Teva: Asthma and COPD Therapies Revenue($m) and AGR(%), 2016-2027
  • Figure 10.1: Asthma and COPD Therapies Market: Strengths and Weaknesses, 2016-2027
  • Figure 10.2: Asthma and COPD Therapies Market: Opportunities and Threats, 2016-2027
  • Figure 10.3: Porter's Five Forces Analysis of the Asthma and COPD Therapies Market, 2016-2027
  • Figure 12.1: World Asthma and COPD Therapies Market Forecast: Revenues($m) by Therapeutic Area, 2016-2027

Companies Listed

  • 3M Drug Delivery Systems
  • AB Science
  • Actavis
  • Alcon
  • Alembic
  • Allen and Hanburys
  • Allergan
  • Almirall
  • Apotex
  • Ario Pharma
  • Array BioPharma
  • Aspen Pharmacare
  • Astellas Pharma
  • AstraZeneca
  • Aurobindo Pharma
  • Bellephron
  • Ben Vue Laboratories
  • BioWa
  • BioXpress Therapeutics
  • Boehringer Ingelheim
  • Breath Limited
  • Bristol-Meyer Squibbs
  • Catalent Pharma Solutions
  • Cephalon
  • Ception Therapeutics
  • Chiesi Pharmaceuticals
  • Ciba-Geigy
  • Cipla
  • Circassia Pharmaceuticals
  • CVS Caremark
  • Daewoong Pharmaceutical
  • Dainippon Sumimoto
  • Dr. Reddy's Laboratories
  • Express Scripts
  • Forest Pharmaceuticals
  • Fountain Biopharma
  • Genentech(Roche)
  • Grifols
  • GSK
  • Hikma Pharmaceuticals
  • Ikaria
  • Invion
  • Kamada
  • Kyorin Pharmaceuticals
  • Kyowa Hakko Kirin
  • Lilly
  • Mariposa
  • MedicNova
  • Medimmune
  • Menarini
  • Merck & Co.
  • Mylan
  • Novartis
  • Nycomed
  • Omega Pharma
  • Orion Pharmaceuticals
  • Pearl Therapeutics
  • Perrigo
  • Pfizer
  • Prosonix
  • Reckitt Becnkiser
  • Regeneron
  • Roche
  • Roxane Laboratories
  • Sandoz(Novaris)
  • Sanofi
  • Schering-Plough's
  • SkyePharma
  • Sofotec
  • Stempeutics
  • Sunovion Pharmaceuticals
  • Synairgen
  • Takeda Pharmaceuticals
  • Tanox
  • Teva
  • Theravance
  • Vectura
  • Viatris
  • Watson(Actavis)

Organisations Mentioned in the Report:

  • American Lung Association
  • Bank of Spain
  • Bundesministerium fur Gesundheit(German Ministry of Health)
  • Brazilian Unified Health System(SUS)
  • Department of Pharmaceuticals(India)
  • European Lung Foundation
  • European Respiratory Foundation
  • European Respiratory Society
  • Federal Commission for the Protection against Sanitary Risk(COFEPRIS)
  • Global Initiative for Asthma(GINA)
  • Global Initiative for Chronic Obstructive Lung Disease(GOLD)
  • Italian Medicines Agency(AIFA)
  • Italian Servicio Sanitario Nazionale(SSN)
  • Japanese Pharmaceuticals and Medical Devices Agency
  • Pan-American Health Organization(PAHO)
  • Seguro Popular(Mexico)
  • UK National Health Service(NHS)
  • US Centers For Disease Control and Prevention(CDC)
  • US Food and Drug Administration(FDA)
  • US Institutes of Health
  • US National Blood, Heart and Lung Institute
  • World Health Organization(WHO)
Back to Top